• NurExone Biologic received a notice of patent grant in South Korea covering ExoPTEN, its lead exosome-based therapeutic candidate for nerve injury.
• The patent covers use of exosomes as a drug delivery system to carry PTEN-targeted therapeutic cargo.
• The South Korean grant expands an ExoPTEN patent portfolio that includes issued patents in the US, Japan, Israel, and Russia, with additional applications pending in other jurisdictions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NurExone Biologic Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605191604PRIMZONEFULLFEED9723319) on May 19, 2026, and is solely responsible for the information contained therein.